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  Hip fractures in the elderly population have become a 
‘disease’ with increasing incidence.
  Most of the geriatric patients are affected by a number of 
comorbidities.
  Coagulopathies continue to be a special point of inter-
est for the orthopaedic trauma surgeon, with the man-
agement of this high-risk group of patients a hot topic of 
debate among the orthopaedic community.
  While a universal consensus on how to manage thrombo-
prophylaxis for this special cohort of patients has not been 
reached, multiple attempts to define a widely accepted 
protocol have been published.
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Introduction
Approximately 77 000 proximal hip fractures occur in the 
United Kingdom annually, accounting for 1.5 million bed-
days, at an inpatient cost of £2 billion.1,2 The majority of 
them (65 000) occur in England, with a median post-oper-
ative length of stay (LOS) of 23 days and a 30-day mortal-
ity of between approximately 8% and 10% which has 
remained constant for the last two decades.2
The majority (95%) of hip fractures occur in patients 
over the age of 60 years, 75% of which occur in females.1,2 
More than 98% of fractures are treated surgically in order 
to reduce the risk of development of complications (pneu-
monia, pressure sores, deep vein thrombosis, respiratory 
insufficiency, etc) and to facilitate early mobilisation and 
prompt hospital discharge. It is of note that 25% of 
patients with hip fractures have at least moderate cogni-
tive impairment (abbreviated mental test score less than 
7), 20% are institutionalised and 50% require walking aids 
or are immobile.1,2
One of the major post-surgical complications following 
hip fracture surgery is the development of deep vein throm-
bosis (DVT) and pulmonary embolism (PE).1 The incidence 
of DVT has been reported to be between 1% and 3% 
approximately, whereas PE is in the region of 0.5% and 3%.3 
Nonetheless, DVT occurs in approximately 37% of patients 
with hip fracture and pulmonary embolism in 6%; these fig-
ures are derived from research studies employing veno-
grams or VQ scans in a large cohort of patients, therefore 
representing the true incidence of asymptomatic events.3
It is of interest that clinicians managing this cohort of 
patients usually have to deal with two possible case sce-
narios: patients presenting with no current intake of anti-
coagulation therapy; and patients who are already taking 
anticoagulation drugs for pre-existing medical conditions.
The aim of this study is to report on the available proto-
cols for prevention of thromboembolic events in patients 
admitted with proximal femoral fractures who are not 
receiving any anticoagulation therapy, and to investigate 
current trends of patients who are already on treatment 
for pre-existing medical conditions.
Materials and Methods
This study was divided into two parts.
Part A focussed on the currently acceptable protocols 
of thromboprophylaxis in patients presenting with a hip 
fracture without taking any anticoagulant therapy for 
other medical conditions. Large-scale studies providing 
evidence of the need for treatment were assessed, as well 
as existing guidelines.3,4
Part B focussed on patients presenting with a hip frac-
ture who were already on anticoagulation therapy for dif-
ferent medical reasons. A literature search was conducted 
using PubMed, the Cochrane Library and Embase data-
bases using the keywords ‘anticoagulation therapy’, 
‘proximal femur fracture’ and ‘hip fracture’. Manuscripts 
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were eligible for inclusion if they described comparative 
studies of patients who sustained hip fracture and were 
under any anticoagulation therapy (warfarin, aspirin, 
dipyridamole, clopidogrel) with a control group and only 
in the English language. Exclusion criteria included manu-
scripts that did not compare any patient group and did 
not describe any inversion protocol.
Details were extracted from each study, such as num-
ber of patients, type of anticoagulation treatment that the 
patient was receiving at the time of admission, time to sur-
gery and outcomes and recommendations made. Results 
were shown in tables.
Results
For part A, the following guidelines were reviewed (see 
Table 1).1,3-6 NICE guidelines (CG92) recommend com-
bined VTE prophylaxis with mechanical and pharmaco-
logical methods for patients undergoing hip fracture 
surgery.7 Initiation of mechanical venous thromboembo-
lism (VTE) prophylaxis at admission is advocated by selec-
tion of one of the following methods based on individual 
patient factors: anti-embolism stockings (thigh or knee 
length); foot impulse devices or intermittent pneumatic 
compression devices (thigh- or knee-length). Mechanical 
VTE prophylaxis should continue until the patient’s mobil-
ity is no longer significantly reduced.
Providing there is no contra-indication, chemical VTE 
prophylaxis can be started before surgery by selecting one 
of the following medications. Low molecular weight hep-
arin (LMWH) is started on admission, stopped 12 h before 
surgery and restarted 6 to 12 h post-operatively. Unfrac-
tioned heparin (UFH) for patients with severe renal impair-
ment or established renal failure is started on admission, 
stopped 12 h before surgery and restarted between 6 and 
12 h after surgery. Fondaparinux sodium is started 6 h 
post-operatively. The pharmacological VTE prophylaxis 
continues for 28 to 35 days post-operatively according to 
the summary of product characteristics.7
The Scottish Intercollegiate Guidelines Network (SIGN)4 
guidelines recommend combined mechanical and chemi-
cal prophylaxis for patients that do not receive any antico-
agulation treatment before sustaining hip fracture.4 Prior 
to surgery, the use of cyclic sequential compression and 
arterial-venous (A-V) foot impulse systems is strongly 
advised and if surgery is delayed, patients should receive 
heparin (UFH or LWMH), which should be stopped 12 h 
before surgery and restarted 6 to 12 h post-operatively. 
Fondaparinux is not recommended before surgery due to 
increased potential complications with neuraxial anaes-
thesia. However, providing there is no contra-indication, 
fondaparinux is recommended post-operatively for 28 
days starting 6 h after surgery. Aspirin is not recom-
mended post-operatively as monotherapy for hip fracture 
surgery.4 The British Orthopaedic Association, in the Blue 
Book of Guidelines on the care of patients with fragility 
fractures states: “Almost ten years ago, a non-consensus 
between units existed regarding the anticoagulation 
chemical VTE prophylaxis pre-operatively. But they advo-
cated the start of Heparin (UFH or LWMH) 6-12 hours after 
surgery for 4 weeks, the early mobilization of the frail 
patient and the simultaneous use of mechanical VTE 
prophylaxis”.6
For part B, out of 108 publications (screened) only five 
met the inclusion criteria (Table 2).8-12
Vitale et  al8 conducted a study among 1634 patients 
presenting to the Columbia Presbyterian Medical Centre 
(CPMC) between 1997 and 2010, who underwent opera-
tive intervention of a hip fracture. Of these, 93 patients 
(5.7%) were identified as having a pre-operative interna-
tional normalised ratio (INR) >1.50 and were taking warfa-
rin on admission. Two study groups comprised the study 
population. The control (watch-and-wait) group consisted 
of patients whose warfarin was held upon admission with-
out any further pre-operative intervention (23 pt). The 
treatment (pharmacological intervention) group consisted 
of patients who underwent pharmacological reversal of 
elevated INR (with vitamin K and/or fresh-frozen plasma 
(FFP)) in addition to their warfarin being held (70 pt). The 
INR at admission was dichotomised such that the values of 
INR at admission above the median value (INR = 2.17) 
were classified as ‘high INR’ and those less than or equal to 
the median value were classified as ‘low INR’. Among 
those with a high INR, patients in the watch-and-wait 
group had a mean time to surgery of 6.8 days and those in 
the treatment group had a mean time to surgery of 2.8 
days. Significant differences were not found among the 
post-operative complication and mortality rates. The 
authors concluded that reversal of warfarin-associated 
coagulopathy with vitamin K and/or FFP is not associated 
with a greater rate of post-operative complications in the 
high-risk geriatric population of patients with hip fractures 
and was found to be a safe alternative to warfarin cessation 
alone, which may result in increased delay to surgery.8
Reversal of high INR is important to avoid a significant 
delay in surgery as suggested by the International Scholarly 
Research Network (ISRN) after a retrospective study con-
ducted in four different hospitals in the UK. Ashuri et al9 retro-
spectively reviewed 1797 hip fractures. Of these, 1740 were 
the control group and the remainder, 57 of whom were on 
warfarin, were divided into two groups. The first group con-
sisted of 16 patients who did not receive any treatment 
(watch-and-wait), and the second group of 41 patients was 
reversed pharmacologically. The mean time to surgery from 
admission in patients not given pharmacological treatment 
was 4.4 days (between 1 and 8 days). The average time to 
surgery from admission in patients given pharmacological 
treatment was 2.4 days (between 1 and 5 days). The study 
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concluded that reversal of warfarin anticoagulation facili-
tates earlier surgery and that a national policy should be 
developed for reversing warfarin anticoagulation in patients 
with hip fractures requiring surgery.9
In another study, Leonidou et al10 compared the effects 
of different warfarin reversal protocols on surgical delay 
and complication rates in patients with hip fractures. The 
medical records 24 patients who were on warfarin and 
sustained a hip fracture, and were reviewed retrospec-
tively. The time to surgery, complication rate and mortal-
ity were recorded as well as the INR on admission and the 
day of operation, the dose, route and time of administra-
tion of vitamin K for reversing the anticoagulation effect of 
warfarin. Patients were divided into four groups based on 
the warfarin reversal treatment. Group 1 (n = 4) included 
patients who did not receive reversal treatment, as their 
admission INR was ≤1.5. Group 2 (n = 6) included patients 
who did not receive reversal treatment even though their 
INR was >1.6. Group 3 (n = 5) included patients who 
received inappropriate reversal treatment (late or 
low-dose oral administration). Group 4 (n = 9) included 
patients who received appropriate reversal treatment in 
terms of dose, route and time of administration. Patients 
on warfarin who did not receive reversal pharmacother-
apy (between 5 and 10 mg of intravenous vitamin K) 
waited longer for surgery compared to those who received 
it (4.4 versus 2.4 days). Six of the patients developed com-
plications, including gastro-intestinal bleeding, ileus, 
chest infection, respiratory failure and peri-operative car-
diac arrest; one patient died. Group A was excluded from 
further analysis. In Groups B, C and D, the mean times to 
surgery were 2.3, 2.6 and 1.2 days and the complication 
rates were 67%, 20% and 11% respectively.10 The figures 
in this review make interpretation difficult.
Eardley et al11 studied the time to surgery of the war-
farinised patients affected with hip fractures and the eco-
nomic impact on the best tariff practice (BTP) over the 
study period of 32 months.
Table 1. Protocols of thromboprophylaxis in patients presenting with a hip fracture without taking any pharmacological agents for anticoagulation
Author Year VTE chemoprophylaxis pre-op Mechanical VTE 
prophylaxis pre-op
VTE chemoprophylaxis 
post-op
Mechanical VTE 
prophylaxis post-op
The National Hip Fracture 
Database National Report, 
2010.1
2010 1. LMWH starting on admission. Stop 
12 h before surgery, restart 6 to 12 h 
after surgery
1. Anti-embolism 
stockings
Heparin (UFH or LMWH), 
fondaparinux × 28 to 
35 days
Continue mechanical 
VTE prophylaxis until 
patient no longer has 
significantly reduced 
mobility
2. UFH (starting on admission for 
patients with renal failure). Stop 12 h 
before surgery and restart 6 to 12 h 
after surgery
2. Foot impulse device
3. Fondaparinux is not recommended 
before surgery. If used should stop 24 h 
before surgery
3. Intermittent 
pneumatic compression 
devices
NICE3 2011 1. LMWH starting on admission. Stop 
12 h before surgery, restart 6 to 12 h 
after surgery
1. Anti-embolism 
stockings
Heparin (UFH or LMWH), 
fondaparinux × 28 to 
35 days
Continue mechanical 
VTE prophylaxis until 
patient no longer has 
significantly reduced 
mobility
2. UFH (starting on admission for 
patients with renal failure). Stop 12 h 
before surgery and restart 6 to 12 h 
after surgery
2. Foot impulse device
3. Fondaparinux is not recommended 
before surgery. If used should stop 24 h 
before surgery
3. Intermittent 
pneumatic compression 
devices
Scottish Intercollegiate 
Guidelines Network 
(SIGN)4
2009 “If surgery is delayed patients should 
receive thromboprophylaxis with 
heparin (UFH or LMWH. Fondaparinux 
is not recommended before surgery”
Cyclic sequential 
compression and arterial 
venous (A-V) foot 
impulse systems
Fondaparinux × 28 
days or heparin (UFH 
or LMWH). Aspirin as 
a monotherapy is not 
recommended
Continue mechanical 
VTE prophylaxis until 
patient no longer has 
significantly reduced 
mobility
National Institute for 
Health and Care Excellence 
(NICE)5
2015 1. Low molecular weight heparin 
(LMWH) starting on admission. Stop  
12 h before surgery, restart 6 to 12 h 
after surgery
1. Anti-embolism 
stockings
Heparin (UFH or LMWH), 
fondaparinux × 28 to 
35 days
Continue mechanical 
VTE prophylaxis until 
patient no longer has 
significantly reduced 
mobility2. Unfractioned heparin (UFH) (starting 
on admission for patients with renal 
failure). Stop 12 h before surgery and 
restart 6 to 12 h after surgery
2. Foot impulse device
3. Fondaparinux is not recommended 
before surgery. If used should stop 24 h 
before surgery
3. Intermittent 
pneumatic compression 
devices
Blue Book on Fragility 
Fracture Care, British 
Orthopaedic Association 
(BOA)6
2007 Controversy over thromboprophylaxis 
if it remains as effective its initiation is 
delayed until after surgery
1. Anti-embolism 
stockings
Chemoprophylaxis 
(fondaparinux or LMWH) 
continued for 4 weeks 
after surgery
Advocates mechanical 
prophylaxis and early 
mobilisation2. Foot impulse device
3. Intermittent 
pneumatic compression 
devices
VTE: venous thromboembolism
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A total of 1054 patients were admitted with hip frac-
tures, 86 of them were taking warfarin on admission and 
were retrospectively assessed. Non-operative manage-
ment accounted for three patients in the warfarin group 
and 30 patients in the non-warfarin control group. Fol-
lowing exclusion, there were 83 patients in the warfarin 
group and 908 patients in the control group. The param-
eters measured were: time to theatre; LOS; Nottingham 
Hip Fracture Score (NHFS); and predicted 30-day mortal-
ity. Large differences were not found between groups on 
the LOS, the NHFS and the predicted percentage of 
30-day mortality. However, a statistically significant dif-
ference was seen in the time to theatre between the war-
farin group and the control group. The average time to 
theatre for the non-warfarinised group was 32.09 h com-
pared with 53.71 h in the warfarinised group. In terms of 
BTP, 28% (257 of 908) of non-warfarinised patients 
breached the 36 h window on time to theatre, in contrast 
with 79% (66 of 83) in the warfarin group. The loss of BTP 
in the warfarin group over the study period equated to a 
loss of £80 000 in revenue within the unit. The authors 
went on to suggest that bedside INR testing should be 
considered as a means of investigation in these patients, 
an approach that could further reduce delays in blood 
sample processing and resultant IV vitamin K prescription 
where required, reinforcing near-patient care and insti-
gating the culture of corporate responsibility for the early 
management of patients with hip fracture on warfarin.11
Crawford et al12 reviewed records of 330 patients with 
hip fractures. A total of 167 patients were controls; 30 
patients were on warfarin, 105 patients were on aspirin 
and 28 patients were on clopidogrel. Hospital mortality, 
time from admission to surgery, LOS, return to theatre 
and post-operative complications (wound infection, DVT 
and PE) were assessed. The non-warfarinised patients 
(aspirin, clopidogrel, control) were the group that had a 
mean time to theatre of 1.7 days compared with warfarin-
ised patients who had 3.3 days to theatre. All the other 
parameters included in the study were found to have no 
significant deviations from other studies. The authors con-
cluded that it is safe to continue aspirin and clopidogrel 
prior to surgical treatment for femoral neck fracture. The 
risk of delaying surgery outweighs the peri-operative 
bleeding risk.12
Discussion
Femoral neck fractures constitute increasingly common 
injuries in the elderly population. Such fractures are ortho-
paedic emergencies that require a multi-disciplinary 
approach and simultaneous involvement of different spe-
cialties for a safe and prompt access to the operating thea-
tre for stabilisation of the fractures and rapid 
rehabilitation.
Fracture fixation is mandatory for pain relief, early 
mobilisation and rehabilitation. DVT and PE represent rec-
ognised post-operative complications. It is currently 
accepted that the incidence of asymptomatic thrombo-
embolic events is greater when compared to symptomatic 
ones.3 Consequently, an effort has been made to establish 
national guidelines in order to minimise the risk of mor-
bidity and mortality.
The NICE and SIGN guidelines include a combined VTE 
prophylaxis approach with both mechanical and pharmaco-
logical methods. Mechanical means of prophylaxis include 
anti-embolism stockings, foot impulse devices and intermit-
tent pneumatic compression devices. Chemical prophylaxis 
includes the administration of LMWH and UFH for patients 
with severe renal impairment or established renal failure. 
Fondaparinux sodium can also be used, starting 6 h after 
surgery. Overall, chemical prophylaxis is recommended for 
a period of 28 to 35 days post-operatively.3,4
Special emphasis is given to the patient with hip frac-
ture and taking different anticoagulant therapies. Those on 
Table 2. Studies on patients presenting with a hip fracture and who are 
on anticoagulation therapy for different medical reasons
Author Year N = Anticoagulation 
type and patient
Time to theatre
Vitale, USA8 2011 1634 Group A: 70 patients 
on warfarin
2.8 days
Group B: 23 control 
patients (watch-and- 
wait)
6.8 days
Ashouri, UK9 2011 1797 57 patients on 
warfarin divided
 
Group A: 16 patient 
sin watch-and-wait
4.4 days
Group B: 41 
patients reversed 
pharmacologically
2.4 days
Leonidou, 
UK10
2013 24 Group A: not receive 
reversal 4 patients
Excluded
Group B: 
appropriately 
reversed 9 patients
1.2 days
Group C: not 
reversed 6 patients
2.3 days
Group D: 
inappropriately 
reversed 5 patients
2.6 days
Group E: not reversed 
(6 patients) and  
inappropriately 
reversed (5 patients)
2.4 days
Eardley, 
UK11
2014 1024 Group A: 908 control 
patients
32.09 h
Group B: 83 patients 
on warfarin
53.71 h
Crawford, 
Australia12
2015 330 Group A: 167 control 
patients
1.6 days
Group B: 30 patients 
on warfarin
3.3 days
Group C: 105 
patients on aspirin
1.8 days
Group D: 28 patients 
on clopidogrel
1.6 days
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aspirin and antiplatelet agents represent a group that is 
not substantially different from patients that do not receive 
any treatment. However, those on warfarin demonstrate 
significant differences, whether they have pharmacologi-
cal reversal of the anticoagulant effect of warfarin or not.
Patients at risk of cerebrovascular events, PE, atrial 
fibrillation, acute thromboembolism and those with pros-
thetic heart valves are treated with oral anticoagulants 
such as warfarin.13 Warfarin is a long-term anticoagulant 
antagonising the reversing effect of vitamin K, which 
decreases the production of modified clotting factors II, 
VII, IX and X. After the administration of warfarin is ceased, 
it may take up to five days for the INR to return to normal 
values because of the long half-life of warfarin. By con-
trast, vitamin K disperses the liver reserves, triggering the 
opposite effect of warfarin.14
A lot of time has been spent debating ‘watch-and-wait 
or reverse’. However, it is well known that surgery can be 
planned earlier by reversing the effect of warfarin with 
vitamin K.15 Ashouri et al16 reported a delay of two days in 
a cohort of patients who did not receive reversal 
treatment.9
The SIGN has recommended reversing the pharmaco-
logical effect of warfarin either with oral or intravenous 
vitamin K in order to accelerate hip fracture surgery in the 
elderly. Of note, the highest INR decrease was observed 
4 h after the first administration dose. A dose of between 
1 and 2.5 mg administered either orally or intravenously 
has been established as a safe protocol.7
NICE guidelines underline the importance of the 
prompt surgical management of elderly patients with fra-
gility hip fractures within the first 36 h, and it has been 
highlighted that delays related to anticoagulation are 
unjustified.3,5 Where it is deemed appropriate, FFP should 
be used in accordance with national guidelines from the 
British Committee for Standards in Haematology. To 
reduce the risk of surgical bleeding, the American College 
of Chest Physicians recommends stopping the antiplatelet 
therapy and not delaying the transfusion with platelets, 
except in cases with excessive surgical bleeding.7
Up to 4% of patients take clopidogrel, an irreversible 
inhibitor of platelet aggregation. Clopidogrel is generally 
not stopped on admission, especially in patients with 
drug-eluting coronary stents. Operation should not be 
delayed, nor should platelets be administered prophylac-
tically, but marginally greater blood loss should be 
expected. Although this is associated with an increased 
risk of intra-operative bleeding and also an increased risk 
of spinal haematoma where regional anaesthesia is 
employed, the recent SIGN guidelines recommend that 
surgery should not be delayed.4
Aspirin is taken regularly by 30% of patients presenting 
with hip fracture.8 There is a risk of significant bleeding if aspi-
rin is taken in combination with other thromboprophylactic 
medication. Aspirin may be withheld during inpatient stay 
unless indicated for unstable angina or recent/frequent tran-
sient ischaemic attacks.
Overall, one can argue that a non-consensus exists 
about which protocol to follow. However, it is commonly 
agreed and demonstrated from the above studies that 
patients who received vitamin K orally, subcutaneously or 
intravenously have seen a benefit. The time to surgery was 
reduced with continuous positive consequences, includ-
ing a reduction in LOS and development of post-operative 
complications.8-10,16
The current evidence favours the use of oral vitamin K 
for anticoagulation reversal in hip fracture patients. The 
need for further prospective studies to establish a proto-
col to apply for patients already receiving anticoagulant 
therapy is mandatory in order to acquire strong evi-
dence for the establishment of a robust pathway at a 
national level.
The so-called new oral anticoagulants (NOAs) such as 
dabigatran, rivaroxaban and apaxiban have recently been 
proposed for the prevention and treatment of thrombosis. 
Their mechanism of action modifies the activity of throm-
bin and factor Xa.17
The approved dose of rivaroxaban is 10 mg daily begin-
ning 6 to 10 h after surgery, and continued for five weeks 
following total hip arthroplasty (THA) and two weeks after 
total knee arthroplasty (TKA). It is excreted predominantly 
by the kidneys (70%) with a small component excreted by 
the liver (30%).18 Dabigatran is administered once daily. It 
has rapid onset of activity and predictable anticoagulation 
activity. Its excretion is renal (80%) and is contra-indicated 
for patients with severe renal failure (creatinine clearance 
under 30 mL/min), but it can be used at reduced dose in 
patients with moderate renal impairment with creatinine 
clearance of 30 to 50 mL/min.19 Apixaban is administered 
twice a day and is only 30% excreted by the kidneys. For 
this reason it is considered as the anticoagulant of choice 
for patients with renal impairment.20 Regulatory agencies 
have approved them with specific indications based upon 
results from clinical trials where their efficiency and safety 
have compared with the traditional and well established 
drugs, such as warfarin.
The NOAs are well studied, having in general such 
advantages as low drug interaction and quick on set and 
offset. They do not require laboratory monitoring in a 
fixed dose, but their disadvantage is that they do not have 
an antagonist to reverse their pharmacologic effect. Usu-
ally, NOAs are prescribed in patients undergoing THA and 
TKA. Attempts to extend their indications for lower limb 
fracture surgery have been made, but there still does not 
exist strong evidence with regard to their use in patients 
with fragility fractures around the hip. Further studies are 
desirable in order to establish their routine use in hip frac-
ture surgery.
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Conclusion
Patients presenting with hip fractures are at high risk of 
developing DVT and PE. Those that do not receive any anti-
coagulation therapy on admission for medical reasons are 
easy to manage with the implementation of existing national 
protocols. Patients who are already on anticoagulation 
treatment for pre-existing medical conditions are more 
complex to manage. A national agreement needs to be 
developed by surgeons, haematologists and cardiologists in 
order to avoid delays in patient management and reduce 
further complications related to hip fracture surgery. 
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